Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Perioperative Medicine

Date Submitted: Oct 31, 2021
Date Accepted: Oct 6, 2022

The final, peer-reviewed published version of this preprint can be found here:

The Use of Machine Learning to Reduce Overtreatment of the Axilla in Breast Cancer: Retrospective Cohort Study

Jozsa F, Baker R, Kelly P, Ahmed M, Douek M

The Use of Machine Learning to Reduce Overtreatment of the Axilla in Breast Cancer: Retrospective Cohort Study

JMIR Perioper Med 2022;5(1):e34600

DOI: 10.2196/34600

PMID: 36378516

PMCID: 9709674

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Can machine learning be used to reduce overtreatment of the axilla in breast cancer? Results from a retrospective cohort study

  • Felix Jozsa; 
  • Rose Baker; 
  • Peter Kelly; 
  • Muneer Ahmed; 
  • Michael Douek

ABSTRACT

Background:

Patients with early breast cancer undergoing primary surgery who have low axillary nodal burden can safely forego axillary node clearance (ANC). However, routine use of axillary ultrasound (AUS) leads to 43% of patients in this group having ANC unnecessarily following a positive AUS. The intersection of machine learning with medicine can provide innovative ways to understand specific risk within large patient data sets, but this has not yet been trialled in the arena of axillary node management in breast cancer.

Objective:

To assess if machine learning techniques could be used to improve pre-operative identification of patients with low and high axillary metastatic burden.

Methods:

A single-centre retrospective analysis was performed on patients with breast cancer who had a preoperative axillary ultrasound, and the specificity and sensitivity of AUS were calculated. Machine learning and standard statistical methods were applied to the data to see if, when used preoperatively, they could have improved the accuracy of AUS to better discern between high and low axillary burden.

Results:

The study included 459 patients; 31% (n=142) had a positive AUS, and, among this group, 62% (n=88) had two or fewer macrometastatic nodes at ANC. When applied to the dataset, logistic regression outperformed AUS and machine learning methods with a specificity of 0.950, correctly identifying 66 patients in this group who had been incorrectly classed as having high axillary burden by AUS alone. Of all the methods, the artificial neural network had the highest accuracy (0.919). Interestingly, AUS had the highest sensitivity of all methods (0.777), underlining its utility in this setting.

Conclusions:

Machine learning greatly improves identification of the important subgroup of patients with no palpable axillary disease, positive ultrasound, and more than two metastatically involved nodes. A negative ultrasound in patients with no palpable lymphadenopathy is highly indicative of low burden and it is unclear if sentinel node biopsy adds value in this situation. Clinical Trial: n/a


 Citation

Please cite as:

Jozsa F, Baker R, Kelly P, Ahmed M, Douek M

The Use of Machine Learning to Reduce Overtreatment of the Axilla in Breast Cancer: Retrospective Cohort Study

JMIR Perioper Med 2022;5(1):e34600

DOI: 10.2196/34600

PMID: 36378516

PMCID: 9709674

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.